The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...

In early March 2026, Tenaya Therapeutics reported a reduced full-year net loss of US$90.6 million and highlighted encouraging preclinical and Phase 1 data for its HDAC6 inhibitor TN-301 in Duchenne ...

ITF Therapeutics LLC, the U.S. rare disease affiliate of Italfarmaco, today announced the presentation of ten abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Key HighlightsResearchers identified distinct tumor-immune ecologies that differentiate stable disease from progressive disease in non-small cell lung ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Shumate Engineering has started work on 16 hyperscale data centers in the U.S. spread across Texas, Missouri and Arizona that will total about 5.7 gigawatts of processing power.

A preclinical study led by the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Institut de Myologie and the Sant Pau Research Institute, has analyzed the role of the protein ...